J Korean Med Sci.  2022 May;37(21):e179. 10.3346/jkms.2022.37.e179.

Letter to the Editor: PropacetamolInduced Rhabdomyolysis or COVIDVaccine-Related Inflammatory Myopathy?

• Finsterer J

• KMID: 2530120
• DOI: http://doi.org/10.3346/jkms.2022.37.e179

Reference

1. Kim JH, Kim JH, Woo CG. Clinicopathological characteristics of inflammatory myositis induced by COVID-19 vaccine (Pfizer-BioNTech BNT162b2): a case report. J Korean Med Sci. 2022; 37(11):e91. PMID: 35315602.

2. Choi SJ, Moon S, Choi UY, Chun YH, Lee JH, Rhim JW, et al. The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial. BMC Pediatr. 2018; 18(1):201. PMID: 29935535.

3. Tsai MS, Wang YH, Lai YY, Tsou HK, Liou GG, Ko JL, et al. Kaempferol protects against propacetamol-induced acute liver injury through CYP2E1 inactivation, UGT1A1 activation, and attenuation of oxidative stress, inflammation and apoptosis in mice. Toxicol Lett. 2018; 290:97–109. PMID: 29574133.

4. Lameiras JL, da Costa OT, Moroni FT, Araújo Jde R, Caranhas SM, Marques CM, et al. Systemic rhabdomyolysis induced by venom of freshwater stingrays Plesiotrygon iwamae and Potamotrygon motoro (Chondrichthyes-Potamotrygonidae) from the Amazon Basin. Toxicon. 2014; 77:105–113. PMID: 24211759.

5. Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. 2022; Forthcoming. DOI: 10.1001/jamacardio.2022.0583.